"Waxaan ka ogaanay isticmaalkeena DBS ku dhawaad labaatan sano si aan u daweyno ciladaha dhaqdhaqaaqa sida Parkinson's iyo gariir lama huraan ah in nidaamku yahay daweyn badbaado leh oo guud ahaan si wanaagsan loo dulqaatay," ayuu yiri Dr. Whiting. In ka badan 160,000 qof oo adduunka oo dhan ah ayaa helay daaweynta DBS ee xaaladahaas.

AHN waa mid ka mid ah 20ka goobood ee Maraykanka ee loo doortay inay ka qaybqaataan Daraasadda ADvance II oo sidoo kale lagu qabto Kanada iyo Jarmalka.

Cudurka Alzheimers waa nooca ugu badan ee waallida. Qiyaastii 6.2 milyan, ama mid ka mid ah sagaalkii Maraykan ah ee da'doodu tahay 65 iyo ka weyn ayaa la nool Alzheimers; 72 boqolkiiba waa 75 jir ama ka weyn. Alzheimer's waa cudur horusocod ah oo marxaladihiisa dambe, neerfayaasha qaybaha maskaxda ee qofka u suurtageliya inuu fuliyo hawlaha aasaasiga ah ee jidhka, sida socodka iyo liqidda. Cudurka ayaa ugu dambeyntii dilaa ah oo aan la helin dawo la og yahay.

DBS ee Alzheimers waxay ku lug leedahay isticmaalka qalab la rakibay oo la mid ah wadnaha garaaca wadnaha iyo laba fiilo oo ku dheggan kuwaas oo si toos ah u keena garaaca korantada khafiifka ah aagga maskaxda ee loo yaqaan fornix (DBS-f), kaas oo la xidhiidha xusuusta iyo barashada. Kicinta korantada ayaa la rumeysan yahay inay dhaqaajiso wareegga xusuusta ee maskaxda si ay u afeysato shaqadeeda.

Daraasadda la kala soocay, laba-indho-la'aanta ah waxay socon doontaa afar sano ka qaybgalayaasha, kuwaas oo mid walba uu mari doono qiimeynta Alzheimers oo la jaan-qaaday ka hor inta aan la gelin neurostimulator-ka. Natiijooyinka qiimayntan jireed, maskaxeed, iyo garaadka ayaa loo isticmaali doonaa sida cabbirka aasaasiga ah maadaama si joogto ah loo qiimeeyo heerka horumarka Alzheimers inta lagu jiro daraasadda.

Tallaalka ka dib, saddex-meelood laba meel bukaannada ayaa la kala soocay si loo hawlgeliyo neurostimulator-kooda oo saddex-meeloodow meel ayaa laga saari doonaa qalabkooda. Bukaanka uu qalabkoodu dansan yahay bilowga daraasadda waxa la hawlgelinayaa 12 bilood ka dib.

Inta lagu jiro tijaabada bukaan-socodka, ka-qaybgalayaasha daraasadda waxaa kormeeri doona koox cilmi-nafsiyeedyo badan oo AHN neurologists, dhakhaatiirta cilmi-nafsiga iyo dhakhaatiirta neerfayaasha, oo ay ku jiraan Dr. Whiting iyo saaxiibkii AHN neurosurgeon iyo khabiir DBS Nestor Tomycz, MD.

Si aad ugu qalanto tijaabada, bukaanadu waa inay ahaadaan 65 ama ka weyn, laga helay Alzheimers fudud, caafimaadkoodu si kale fiican yahay, oo ay leeyihiin daryeele ama xubin qoys oo loo qoondeeyay oo u raaci doona booqashooyinka dhakhtarka.

"Natiijooyinka wejiyadii hore ee tijaabadan caafimaad ayaa ah kuwo rajo leh waxayna tilmaamayaan in daawadu ay ka faa'iidaysan karto bukaannada qaba Alzheimers fudud iyadoo la dejinayo lana hagaajinayo shaqadooda garashada," ayuu yiri Dr. Whiting. "In la yiraahdo natiijada guusha leh ee daraasaddan waxay u noqon kartaa nolosha malaayiin Maraykan ah oo ay saameeyeen tan daciifka ah, cudurka dilaaga ah maaha mid la dhayalsan karo. Aad ayaan ugu faraxsanahay inaan ka mid noqono kooxaha qalliinka caanka ah ee adduunka oo siinaya bukaannada Alzheimers inay helaan hal-abuurkan.

Hoggaanka Dr. Whiting, Isbitaalka Guud ee AHN ee Allegheny ayaa muddo dheer safka hore kaga jiray dadaallada hormuudka ah ee lagu hormarinayo isticmaalka kicinta maskaxda qoto dheer. Isbitaalku wuxuu ahaa kii ugu horreeyay ee galbeedka Pennsylvania si uu u isticmaalo tignoolajiyada lagu daweeyo gariirka muhiimka ah iyo Cudurka Parkinson, iyo dhawaanahan, Dr. Whiting iyo kooxdiisu waxay bilaabeen wajigii labaad ee tijaabo caafimaad oo sahaminta waxtarka DBS si ay uga caawiso maaraynta buurnaanta jirrada.

MAXAA LAGU QAADAYAA MAQAALKAN:

DBS for Alzheimer’s involves the use of an implanted device similar to a heart pacemaker and two attached wires that deliver mild electrical pulses directly to an area of the brain called the fornix (DBS-f), which is associated with memory and learning.
Alzheimer’s is a progressive disease and in its late stages, the neurons in parts of the brain that enable a person to carry out basic bodily functions, such as walking and swallowing are affected.
The results of this physical, psychological, and cognitive evaluation will be used as a baseline measurement as they are regularly assessed for the rate of Alzheimer’s progression throughout the duration of the study.